TEM

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the second quarter ended June 30, 2026, on Thursday, July 30, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The.

Tempus receives a Buy rating, leveraging a unique AI-driven diagnostics and data platform with expanding FDA-approved offerings. Recent FDA approval for xT CDx's tumor-only indication and the upcoming xH assay broaden TEM's clinical reach and addressable markets. AI-powered Lens and Next platforms drive adoption among top biopharma and improve clinical outcomes, reinforcing TEM's data flywheel and competitive moat.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a research collaboration with Angiosarcoma Awareness, Inc. to accelerate data-driven research in angiosarcoma, one of the rarest and most aggressive cancers. Angiosarcoma is a rare malignant tumor that starts in endothelial cells, which form the inner lining of blood vessels. It is known for its aggressive behavior, rapid progres.

TEM's diagnostics growth and expanding data deals support momentum, but sizable GAAP losses and execution challenges could keep shares volatile.

Tempus AI (TEM) has consolidated near trend lows for four months, forming a double bottom with breakout resistance at $54.75 and a first target near $64.54.

Tempus AI trades at multi-year lows despite proprietary data advantages and robust AI-driven precision medicine capabilities. The company leverages 500+ petabytes of unique multimodal healthcare data inaccessible to generic AI models. With a market cap under $9B and trading at ~4.5x forward sales, the stock's valuation is compelling given management's 25% annual growth target versus more conservative analyst estimates.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software, which received U.S. Food and Drug Administration clearance in 2024 for predicting the one-year risk of atrial fibrillation or flutter (AF). The study, titled "Multi-Center Validation of an Artificial Intelligence-Enabled ECG Model to Predict 1-Year Risk of Atrial Fibrillation or Fl.

Tempus AI (TEM) now offers an attractive risk-reward setup, with valuations normalized to ~5.7x forward revenue and improved visibility on durable, high-margin revenues. Organic growth remains robust at ~25% for 2026, with no adverse revisions for 2027–2028, and margin mix shifting toward higher-margin Data and Applications segments. Adjusted operating loss has narrowed significantly, and TEM is approaching operating breakeven, supporting the SaaS-like trajectory critical for long-term value.

Tempus AI is rated Strong Buy, leveraging a unique data moat and network effect in healthcare AI. TEM's Diagnostics and Data & Applications segments drive robust 36% YoY revenue growth, with expanding gross margins and deepening pharma partnerships. Massive proprietary datasets (45M+ de-identified records, 500+ PB) underpin AI tools, SaaS revenue, and cross-selling opportunities, creating high barriers to entry.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced peer-reviewed research demonstrating the potential for variant-specific RNA testing to provide greater clarity for patients who receive a variant of uncertain significance (VUS) result from exome testing. The study, published in Genetics in Medicine Open, showcases how targeted RNA analysis using Ambry's ExomeReveal workflow; an in.